Zobrazeno 1 - 6
of 6
pro vyhledávání: '"R. D. Cheshire"'
Autor:
R. D. Cheshire, J. Higson
Publikováno v:
International Journal of Radioactive Materials Transport. 6:41-44
There has been some difficulty across the Nuclear Industry with a consistent approach to the qualification and testing of Industrial Packages. This paper tries to set out an Industry accepted standard.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e63417671c3cddf198d5a24cecf9609
https://doi.org/10.1179/rmt.1995.6.1.41
https://doi.org/10.1179/rmt.1995.6.1.41
Autor:
R. J. Straw, R. D. Cheshire
Publikováno v:
International Journal of Radioactive Materials Transport. 1:127-130
During late 1984 the IAEA Regulations were identified as an area of application for an expert system adviser which could offer many advantages. Over the following year some simple tests were carried out to examine its feasibility, but TRANAID did not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e6c21c47b88e23ed2f62ed6230dfee1
https://doi.org/10.1179/rmt.1990.1.2.127
https://doi.org/10.1179/rmt.1990.1.2.127
Autor:
Vargas HM; Integrated Discovery and Safety Pharmacology, Amgen, Inc., Thousand Oaks, CA, USA., Bass AS; Safety Assessment, Merck Research Laboratories, Boston, MA, USA., Koerner J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Matis-Mitchell S; Discovery Information, AstraZeneca R&D, Wilmington, DE, USA., Pugsley MK; Safety and Exploratory Pharmacology, Janssen R&D, Raritan, NJ, USA., Skinner M; Safety Assessment, AstraZeneca R&D, Cheshire, UK., Burnham M; Safety Assessment, AstraZeneca R&D, Cheshire, UK., Bridgland-Taylor M; Safety Assessment, AstraZeneca R&D, Cheshire, UK., Pettit S; Health and Environmental Sciences Institute, Washington, DC, USA., Valentin JP; Safety Assessment, AstraZeneca R&D, Cheshire, UK.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2015 Aug; Vol. 172 (16), pp. 4002-11. Date of Electronic Publication: 2015 Jul 14.
Autor:
Uno Y; Mitsubishi Tanabe Pharma Co., Chiba, Japan. Electronic address: Uno.Yoshifumi@ma.mt-pharma.co.jp., Kojima H; National Institute of Health Sciences, Tokyo, Japan., Omori T; Kobe University Hospital, Kobe, Japan(1)., Corvi R; Joint Research Centre of the European Commission, Ispra, Italy., Honma M; National Institute of Health Sciences, Tokyo, Japan., Schechtman LM; Innovative Toxicology Consulting, LLC, FL, USA., Tice RR; National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA., Beevers C; Covance Laboratories Ltd., North Yorkshire, UK., De Boeck M; Janssen Research & Development, Beerse, Belgium., Burlinson B; Huntingdon Life Sciences, Cambs, UK., Hobbs CA; Integrated Laboratory Systems, Inc., NC, USA., Kitamoto S; Sumitomo Chemical Co. Ltd., Osaka, Japan., Kraynak AR; Merck Research Laboratories, PA, USA., McNamee J; Health Canada, Ontario, Canada., Nakagawa Y; Hatano Research Institute, Food Drug Safety Center, Kanagawa, Japan., Pant K; BioReliance, MD, USA., Plappert-Helbig U; Novartis, Institutes for BioMedical Research, Basel, Switzerland., Priestley C; AstraZeneca R&D, Cheshire, UK., Takasawa H; LSI Medience,(2) Ibaraki, Japan., Wada K; The Institute of Environmental Toxicology, Ibaraki, Japan., Wirnitzer U; Bayer HealthCare AG, Wuppertal, Germany., Asano N; Kinki University, Osaka, Japan., Escobar PA; Boehringer Ingelheim Pharmaceuticals Inc., CT, USA., Lovell D; St. George's, University of London, London, UK., Morita T; National Institute of Health Sciences, Tokyo, Japan., Nakajima M; University of Shizuoka, Shizuoka, Japan., Ohno Y; National Institute of Health Sciences, Tokyo, Japan., Hayashi M; Biosafety Research Center, Foods, Drugs and Pesticides, Shizuoka, Japan.
Publikováno v:
Mutation research. Genetic toxicology and environmental mutagenesis [Mutat Res Genet Toxicol Environ Mutagen] 2015 Jul; Vol. 786-788, pp. 45-76. Date of Electronic Publication: 2015 Apr 29.
Autor:
Zhu G; Translational Science, Asia & Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, China. Electronic address: mike.zhu@amoydx.com., Ye X; Translational Science, Asia & Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, China., Dong Z; Translational Science, Asia & Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, China., Lu YC; Translational Science, Asia & Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, China., Sun Y; Translational Science, Asia & Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, China., Liu Y; Affiliated Hospital of Academy of Military Medical Science, Beijing, China., McCormack R; Global Medicine Development, AstraZeneca R&D, Cheshire, United Kingdom., Gu Y; Translational Science, Asia & Emerging Markets Innovative Medicine, AstraZeneca R&D, Shanghai, China., Liu X; Affiliated Hospital of Academy of Military Medical Science, Beijing, China. Electronic address: liuxq@medmail.com.cn.
Publikováno v:
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2015 May; Vol. 17 (3), pp. 265-72. Date of Electronic Publication: 2015 Mar 11.
Autor:
Lawrence CL; Department of Safety Pharmacology, Safety Assessment UK, AstraZeneca R&D, Cheshire, UK. Chris.Lawrence@astrazeneca.com, Pollard CE, Hammond TG, Valentin JP
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2008 Aug; Vol. 154 (7), pp. 1516-22. Date of Electronic Publication: 2008 Jun 02.